One area gaining attention is the use of GLP-1 (glucagon-like peptide-1) receptor agonists
But a newer complete study revealed that GLP-1 RA users faced a 108% higher risk of anxiety
The SELECT trial, as noted earlier, went a step further it tested Wegovy in overweight/obese individuals with cardiovascular disease (but without diabetes) and found a 20% reduction in heart attacks, stroke, or CV death ( [67] )

You may also have to pay for the medical provider (whether you see them or not) to review your information and write the prescription (or this may be covered but you have to pay for the medication), they may bundle fees with other services (and you may not want or need these), almost none provide the services and products you will need and they may or may not sell to you (personalized nutrition from a qualified clinician, supplements and other medications (how they may impact and what needs to be changed), additional testing, evaluation and adjustments to all aspects of the above ongoing for optimization. Evaluating whether a telehealth GLP-1 program is medically appropriate often comes down to understanding what level of support is includedand what may cost extra
a case control study
Products labeled for laboratory research are generally not intended for patient treatment